Assessment and Mitigation of Cardiovascular Risk for Prostate Cancer Patients: A Review of the Evidence.

ABSTRACT:

Background

Cardiovascular disease (CVD) is a common comorbidity in patients with prostate cancer. In this review, we summarize the published literature on the association of cardiovascular risk with androgen deprivation therapy (ADT) treatment and explore the potential differences between the gonadotropin-releasing hormone (GnRH) agonists and antagonists and the molecular mechanisms that may be involved. We also provide a practical outlook on the identification of underlying CV risk and explore the different stratification tools available.

Results

While not definitive, the current evidence suggests that GnRH antagonists may be associated with lower rates of certain CV events vs agonists, particularly in patients with preexisting CVD. Risk reduction strategies such as lifesty

SUBMITTER: Davey P 

PROVIDER: S-EPMC9158798 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature